Profile data is unavailable for this security.
About the company
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.
- Revenue in GBP (TTM)21.69k
- Net income in GBP-3.34m
- Incorporated2009
- Employees15.00
- LocationLungLife AI Inc2545 W. Hillcrest Drive, Suite 140THOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 409-9868Fax+1 (805) 855-2003
- Websitehttps://lunglifeai.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
ValiRx Plc | 9.60k | -2.04m |
TheraCryf PLC | 396.00k | -3.14m |
Fusion Antibodies PLC | 1.14m | -2.23m |
IXICO PLC | 6.00m | -1.87m |
ImmuPharma PLC | -69.96k | -2.46m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Synairgen plc | 0.00 | -6.92m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
LungLife AI Inc | 21.69k | -3.34m |
Oxford Biodynamics PLC | 617.00k | -11.11m |
OptiBiotix Health PLC | 644.00k | -2.04m |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Unicorn Asset Management Ltd.as of 31 Aug 2024 | 1.75m | 6.87% |
Lombard Odier Asset Management (Europe) Ltd.as of 22 Mar 2024 | 1.27m | 4.98% |
SVM Asset Management Ltd.as of 31 Dec 2023 | 218.75k | 0.86% |